Morpheus Complete MD1-123/124
Achieve more hits and save money with this exclusive offer on new Morpheus® Complete screen set.
You can learn about the methodolgy behind the screen development in this webinar describing the four-corner method for optimizing Morpheus® hit conditions.
Morpheus Complete contains:
This ever popular screen incorporates a range of low molecular weight compounds that were identified as frequently occurring ordered ligands in more than 33,000 structures from the PDB (PDB data from 2009). This unique screen aims to access novel chemical space left unexplored in conventional screens, primarily by integrating PDB-derived ligands in 8 additive mixes. Each mix contains a number of additives of the same chemical class.
Reference: Gorrec, F. The MORPHEUS protein crystallization screen. Journal Applied Crystallography 42: 1035-42 (2009).
A follow-up to the popular Morpheus® screen, Morpheus® II has been developed using the same approach (including low molecular weight compounds identifed as protein ligands in the PDB in 2015). However, in Morpheus® II, reagents not found in Morpheus or other initial screens have been integrated to access new areas of crystallization space and provide useful hits when other screens have failed.
The 96 conditions include NDSBs, polyamines, amino acids and monosaccharides to increase protein solubility and stability. As with Morpheus®, these are combined in several mixes for efficient screening. Glycerol-like polyols are used for cryoprotection and some heavy atoms are included to aid experimental phasing. Finally, more innovative buffer systems are used.
References: Gorrec, F. The Morpheus II protein crystallization screen. Acta Crystallographica section F Structural Biology Communications 71: 831-837 (2015).
Morpheus III contains a range of small drug-like molecules (Average RMM = 248). The compounds include antibiotics, vitamins, phytochemicals, nucleosides and cholic acid derivatives, which have all been observed bound to structures in the pdb and are known to stabilize proteins, thereby increasing the chances of crystallisation. Morpheus III was designed using precipitant and buffer mixes from Morpheus I as a robust backbone for testing drug-like compounds as additives.